Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 Dec;85(23):9234–9237. doi: 10.1073/pnas.85.23.9234

Effects of passive immunization in patients with the acquired immunodeficiency syndrome-related complex and acquired immunodeficiency syndrome.

A Karpas 1, F Hill 1, M Youle 1, V Cullen 1, J Gray 1, N Byron 1, F Hayhoe 1, M Tenant-Flowers 1, L Howard 1, D Gilgen 1, et al.
PMCID: PMC282713  PMID: 3194422

Abstract

Infection with the human immunodeficiency virus type 1 (HIV-1) is usually followed by a vigorous immune response that temporarily protects against disease progression. After a variable asymptomatic period, acquired immunodeficiency syndrome (AIDS)-related complex (ARC) and AIDS develop in most infected individuals. We have demonstrated that healthy HIV-1-infected individuals have neutralizing antibodies and a high titer of antiviral antibodies. In contrast, AIDS patients have undetectable levels of neutralizing antibodies, low titers of antiviral antibodies, and, frequently, HIV p24 antigenemia. These observations prompted us to attempt passive immunization in ARC and AIDS patients. Ten consistently viral-antigen-positive patients (mean, greater than 6 months) were treated, resulting in sustained clearance of p24 antigen. Patients either maintained or increased their antiviral antibody titers. The raised titers result from increased antibody synthesis by the recipients. Circulating CD4+ cell counts were unchanged after 2 months. By the third month none of these patients remained in hospital. As this treatment was of minimal toxicity, it merits wider evaluation in ARC and AIDS patients.

Full text

PDF
9234

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  2. Bergdahl S., Sönnerborg A., Larsson A., Strannegard O. Declining levels of HIV P24 antigen in serum during treatment with foscarnet. Lancet. 1988 May 7;1(8593):1052–1052. doi: 10.1016/s0140-6736(88)91867-3. [DOI] [PubMed] [Google Scholar]
  3. Clavel F., Guétard D., Brun-Vézinet F., Chamaret S., Rey M. A., Santos-Ferreira M. O., Laurent A. G., Dauguet C., Katlama C., Rouzioux C. Isolation of a new human retrovirus from West African patients with AIDS. Science. 1986 Jul 18;233(4761):343–346. doi: 10.1126/science.2425430. [DOI] [PubMed] [Google Scholar]
  4. Gaines H., Albert J., von Sydow M., Sönnerborg A., Chiodi F., Ehrnst A., Strannegård O., Asjö B. HIV antigenaemia and virus isolation from plasma during primary HIV infection. Lancet. 1987 Jun 6;1(8545):1317–1318. doi: 10.1016/s0140-6736(87)90570-8. [DOI] [PubMed] [Google Scholar]
  5. Hu S. L., Fultz P. N., McClure H. M., Eichberg J. W., Thomas E. K., Zarling J., Singhal M. C., Kosowski S. G., Swenson R. B., Anderson D. C. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature. 1987 Aug 20;328(6132):721–723. doi: 10.1038/328721a0. [DOI] [PubMed] [Google Scholar]
  6. Karpas A., Gillson W., Bevan P. C., Oates J. K. Lytic infection by British AIDS virus and development of rapid cell test for antiviral antibodies. Lancet. 1985 Sep 28;2(8457):695–697. doi: 10.1016/s0140-6736(85)92934-4. [DOI] [PubMed] [Google Scholar]
  7. Karpas A., Hayhoe F. G., Hill F., Anderson M., Tenant-Flower M., Howard L., Oates J. K. Use of Karpas HIV cell test to detect antibodies to HIV-2. Lancet. 1987 Jul 18;2(8551):132–133. doi: 10.1016/s0140-6736(87)92333-6. [DOI] [PubMed] [Google Scholar]
  8. Karpas A. Unusual virus produced by cultured cells from a patient with AIDS. Mol Biol Med. 1983 Nov;1(4):457–459. [PubMed] [Google Scholar]
  9. Moss A. R., Bacchetti P., Osmond D., Krampf W., Chaisson R. E., Stites D., Wilber J., Allain J. P., Carlson J. Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988 Mar 12;296(6624):745–750. doi: 10.1136/bmj.296.6624.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Tsiquaye K. N., Youle M., Chanas A. C. Restriction of sensitivity of HIV-1-antigen ELISA by serum anti-core antibodies. AIDS. 1988 Feb;2(1):41–45. doi: 10.1097/00002030-198802000-00007. [DOI] [PubMed] [Google Scholar]
  11. Weiss R. A., Clapham P. R., Cheingsong-Popov R., Dalgleish A. G., Carne C. A., Weller I. V., Tedder R. S. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature. 1985 Jul 4;316(6023):69–72. doi: 10.1038/316069a0. [DOI] [PubMed] [Google Scholar]
  12. de Wolf F., Lange J. M., Goudsmit J., Cload P., de Gans J., Schellekens P. T., Coutinho R. A., Fiddian A. P., van der Noordaa J. Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet. 1988 Feb 20;1(8582):373–376. doi: 10.1016/s0140-6736(88)91179-8. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES